Generate Biomedicines, Inc.
Research Generate Biomedicines, Inc. (GENB) on Bullrun: market cap USD 2.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGENB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.17B
- Financial periodQ1 2026
- RevenueUSD 7.22M
- Net income-USD 61.45M
- Free cash flow-USD 84.17M
Valuation Snapshot
latest market cap is USD 2.17B.
About Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody;
Frequently asked questions
What is Generate Biomedicines, Inc.'s market cap?
Generate Biomedicines, Inc.'s market capitalization is USD 2.17B.
What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.